Skip to main content
ILYANG PHARMACEUTICAL CO.,LTD logo

ILYANG PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 007570 ISIN · KR7007570005 KO Manufacturing
Open in API
Filings indexed 225 across all filing types
Latest filing 2022-09-16 Transaction in Own Shar…
Country KR South Korea
Listing KO 007570

About ILYANG PHARMACEUTICAL CO.,LTD

https://www.ilyang.co.kr

Ilyang Pharmaceutical, established in 1946, is a research-oriented company that develops and manufactures a diverse portfolio of pharmaceutical products. The company focuses on developing new chemical entities (NCEs) and produces a range of medicines targeting digestive, respiratory, and circulatory system disorders, as well as neoplasms and infectious diseases. Key developments include 'Ilaprazole' (Noltec), a proton pump inhibitor for acid-related disorders, and 'Supect' (Radotinib), a treatment for chronic myeloid leukemia. Its product line also encompasses general drugs, antibiotics, anti-inflammatory agents, nutritional supplements, and well-established consumer health brands like the digestive aid 'NORUMO' and the nutritional drink 'Wonbi-D'.

Recent filings

Filing Released Lang Actions
신탁계약해지결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on the Termination of a Trust Agreement' (신탁계약해지결과보고서) filed by Ilyang Pharmaceutical Co., Ltd. with the Financial Supervisory Service. It details the termination of a share repurchase trust contract and the subsequent status of treasury shares. This type of filing, which reports the completion of a share buyback program via a trust, falls under the category of 'Transaction in Own Shares' (POS).
2022-09-16 Korean
주요사항보고서(자기주식취득신탁계약체결결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange regarding the decision to enter into a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 체결 결정). This type of filing specifically details the company's repurchase or management of its own shares. According to the provided definitions, 'Transaction in Own Shares' (POS) is the correct category for reports concerning the company buying back or selling its own shares.
2022-09-16 Korean
주요사항보고서(자기주식취득신탁계약해지결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding the termination of a trust contract for the acquisition of treasury shares (자기주식취득 신탁계약 해지 결정). This relates to the company's own share management and capital structure. According to the provided definitions, 'Transaction in Own Shares' (POS) is the most accurate category for reports concerning share buybacks, trust contract terminations, or treasury share movements.
2022-09-08 Korean
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for Ilyang Pharmaceutical Co., Ltd., covering the period from January 1, 2022, to June 30, 2022. It contains comprehensive financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2022
2022-08-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a mandatory disclosure of insider trading or changes in share ownership by company directors or major shareholders. According to the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2022-07-15 Korean
투자판단관련주요경영사항(특허권 취득)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Il-Yang Pharmaceutical regarding the acquisition of patents for Parkinson's disease treatment and MERS-CoV treatment. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) in the Korean market, which is a specific type of regulatory disclosure. Since it does not fit into specific categories like M&A, dividends, or financial reports, it is classified as a general regulatory filing.
2022-07-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.